resmetirom-mgl-3196

Description: Resmetirom (formerly known as MGL-3196, MGL 3196) is a novel, highly potent and selective agonist of the thyroid hormone receptor beta (THR-beta) with EC50 value of 0.21 uM. It is currently in clinical trials for the treatment of Non-alcoholic Steatohepatitis. The beneficial effects of thyroid hormone (TH) on lipid levels are primarily due to its action at the thyroid hormone receptor beta (THR-beta) in the liver, while adverse effects, including cardiac effects, are mediated by thyroid hormone receptor alpha (THR-alpha). MGL-3196 is 28-fold selective for THR-beta over THR-alpha in a functional assay. It also showed outstanding safety in a rat heart model and was efficacious in a preclinical model at doses that showed no impact on the central thyroid axis. In reported studies in healthy volunteers, MGL-3196 exhibited an excellent safety profile and decreased LDL cholesterol (LDL-C) and triglycerides (TG) at once daily oral doses of 50 mg or higher given for 2 weeks.

References: J Med Chem. 2014 May 22; 57(10):3912-23.